Purpose. Basal subtype, as approximated by the triplenegative phenotype (ER-PR-Her2-), has correlated with higher LRR in recent studies. Indications for postmastectomy RT (PMRT) in women with 0-3 positive lymph nodes remain unclear. We evaluated the importance of biologic subtype in a cohort of women with LRR after mastectomy. Methods. We identified 22 women with 0-3 positive lymph nodes at our institution who were initially treated with mastectomy (without post-mastectomy radiation), suffered LRRs, and had paraffin-embedded tissue blocks from the primary mastectomy specimen available for staining. None of these women received PMRT. We casecontrol matched these to 29 women with 0-3 positive nodes who had mastectomy (no PMRT) and remained without evidence of disease at last follow-up and had available primary specimens for processing. We matched controls for age (±3 years) and follow-up duration (\5 year vs. more). Paraffin-embedded specimens were used to construct a triple-redundant tissue microarray. We used conditional logistic regressions to study the association between each predictor and LRR. Results were summarized based on odds ratio (OR).
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Results. On univariate analysis, ER?, PR?, or the combination was strongly associated with lower odds of LRR. Basal subtype, as approximated by ER-PR-Her2-(TN), was associated with higher LRR (OR 8.5, p = 0.048). Use of chemotherapy also was associated with lower LRR (OR 0.126, p = 0.0073). Conclusions. Our data are concordant with reports from others demonstrating that TN phenotype is associated with higher LRR and can be considered along with other predictors of LRR when selecting women for PMRT.
Postmastectomy radiation therapy (PMRT) is associated with unequivocal improvements in local-regional recurrence (LRR), disease-free survival, and overall survival. [1] [2] [3] Professional societies, including ASTRO, have issued guidelines on the appropriate indications for PMRT, and there is general consensus that women with advanced presentations and high-risk features are highly likely to benefit from PMRT. 4, 5 The benefit of routine utilization of PMRT for women with intermediate-risk features, such as women with N1a disease, remains more controversial. Large series of patients with 1-3 positive nodes treated in the United States and elsewhere have reported localregional recurrence rates that hover in the range of 6-13 %. [6] [7] [8] Several groups have attempted to classify clinicopathological variables into risk groups for LRR to reliably identify women at higher risk of relapse. For example, Wallgren et al. 9 identified high-grade disease and vascular invasion as risk factors of LRR in women with N1a disease in a cohort of irradiated mastectomy patients. Others have identified multicentric disease, tumor size, and gross extracapsular extension as independent predictors of LRR. 10, 11 Indeed, even selected women with lower risk, node-negative disease may benefit from PMRT. [12] [13] [14] For example, Jagsi et al. 12 examined a cohort of node-negative women treated at Massachusetts General Hospital and identified margin status (\2 mm), premenopausal status, size ([2 cm), and LVI as independent predictors of LRR. It appears that while the overall LRR risks for node-negative and stage IIA patients may be low, the simultaneous presence of several secondary risk factors may indicate a higher than average recurrence risk.
A constellation of adverse clinicopathological features may be a surrogate for adverse underlying disease biology. Thus biologic determinants of LRR may contribute to risk assessment. Recent work has identified biologically distinct subtypes of breast cancer (based on gene expression patterns) that are associated strongly with clinical outcome. These subtypes can be approximated by assessing expression levels of a handful of markers; prognostic information on metastasis and death is conserved even with these phenotypic constructs. 15 Nguyen 16 Freedman et al. 17, 18 similarly identified ''triple-negative'' tumors in their studies looking at the implications of basal subtype. In contrast, Cheang et al. 15 used a 5-marker panel that also included epidermal growth factor receptor and cytokeratin 5/6. Several groups have examined LRR rates as a function of biologic subtype, but the results have been mixed. We attempted to identify whether biologic subtype correlated with LRR in a cohort of mastectomy patients with low-intermediate risk disease burden. Work from our group previously implicated Cox-2 and p53 expression as determinants of LRR, and we evaluated expression of these markers as well. 19, 20 
METHODS AND MATERIALS

Patients
We retrospectively identified 22 women with 0-3 positive nodes who suffered LRRs as either first or only sites of failure after mastectomy and had available paraffin-embedded tissue blocks from the primary mastectomy specimen. None of these women received PMRT. This cohort of postmastectomy LRR cases was matched by age (±3 years) and followup duration (\5 year vs. more) to 28 women with 0-3 positive nodes who had mastectomy (no PMRT) and remained without evidence of disease at last follow-up who also had available tissue from their primary specimens for staining. Patients were identified at one of the two participating institutions: the Yale Cancer Center, New Haven, CT, USA or the Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. Data parameters were abstracted retrospectively from patient medical records and entered into a database. The size of the primary tumor was defined as the largest tumor diameter reported by the pathologist after surgery. Lymph node status was determined by histological evidence of lymph node metastases. The study was conducted after obtaining approval from the participating institutions' Human Investigations Committees.
All patients in this study were treated with mastectomy with or without axillary lymph node dissection, as clinically indicated and based on the standard practice patterns of treating surgeons throughout the interval. Adjuvant chemotherapy was administered to patients as clinically indicated in accordance to the standard practice of medical oncologists during this interval. Adjuvant hormone therapy was routinely given to ER-positive patients. Two patients, both controls, received trastuzumab therapy.
Construction of Tissue Microarray
A pathologist (NB) examined hematoxylin and eosinstained slides of the archived paraffin blocks of breast cancer tissue and circled representative tumor sections. Areas of tumor that were distinct from normal epithelium were identified and marked for subsequent analysis. From these tumor sections, two 0.6-mm cores were extracted using a tissue microarray device (Beecher Instruments, Silver Spring, MD, USA). Three cores were retrieved from each block for inclusion in the tissue microarray (tripleredundancy). Microarrays were cut into 5-lm-thick sections with a tape-based tissue transfer system (Intrumedics, Hackensack, NJ, USA) and processed onto slides.
Staining
Immunohistochemical analysis was performed on 5-lmthick tissue sections that were prepared from formalinfixed, paraffin-embedded archival tissue from the tissue microarray block constructed. Tissue sections were deparaffinized and then quenched in 2 % hydrogen peroxidemethanol solution. Samples were then pretreated to promote antigen retrieval with the DAKO Target Retrieval Solution (DAKO, Carpinteria, CA, USA). A 3 % hydrogen peroxide solution was then used for endogenous peroxidase blocking. Slides were then incubated with rabbit polyclonal antibody DDX1 (1:250; Bethyl Laboratories, Montgomery, TX, USA). Slides were additionally incubated overnight at 4°C with the following antibodies: (1) ER, mouse monoclonal antihuman ER (DAKO); (2) PR, mouse monoclonal antihuman PR (DAKO); (3) HER-2/neu: rabbit polyclonal anti-HER-2/neu oncoprotein (DAKO). Slides were then incubated with secondary antibody, labeled with avidin-biotin complex streptavidin-peroxidase (Elite; Vector Laboratories, Burlingame, CA, USA) and incubated with the chromogen diaminobenzidine tetrahydrochloride as a chromogenic substrate. Finally, slides were counterstained with hematoxylin, dehydrated with ethanol, and mounted. A known positive case was included as a positive control. For the negative control, the primary antibody was replaced with nonimmune mouse serum.
All biomarkers were quantitative and qualitative assessed by a single experienced pathologist (HW) who was blinded to patient outcomes. For cores that were uninterpretable because of tissue loss or lack of tumor cells, a score of ''not applicable'' was given. For each core, the region of predominant staining intensity was scored. ER and PR were assessed by the number of positive-stained nuclei. For HER-2/neu, only membrane staining was scored positive. A numeric score ranging from 0 to 3 that reflected the staining intensity and patterns in 10% or more tumor was used. For HER2 status, numeric score of 3 was considered positive. Cox-2 and p53 expression, previously shown to correlate local failure by our group and others, were similarly investigated.
Statistical Analysis
We used conditional logistic regressions to determine the statistical significance of the association between each predictor and LRR. The odds ratio (OR) and 95 % confidence interval were computed. Fisher's exact test was employed to evaluate the association between biomarker expressions and clinicopathological variables. All statistical tests were two-sided, and p \ 0.05 was considered statistically significant. Due to limited sample size, multivariate analyses were not performed. All results were obtained using SAS version 9.3. Table 1 . There were two missing/unevaluable patients in each cohort due to loss of tissue on the TMA. The median tumor size was 2.7 cm. There were no cases of positive margins in this cohort; four patients had ''close margins'' (two in each group) defined as 0-2 mm. Table 2 demonstrates the proportion of nodal involvement in case and control cohorts. Table 3 presents a univariate analysis of standard clinicopathological variables and odds of LRR. As expected, use of hormonal therapy was strongly associated (Table 4) . Basal subtype, as approximated by ER-PRHer2-(TN) was associated with higher LRR (OR 8.5; 95 % CI 1.02-70.71; p = 0.048). Expression of Cox-2 and p53 did not increase odds of LRR.
RESULTS
A description of study cohort variables is presented in
DISCUSSION
Breast cancer has been classified recently into biologically distinct subtypes (based on gene expression patterns) with varying clinical potential. These subtypes can be approximated by assessing expression levels of just a handful of markers; prognostic information appears to be conserved even with these subtype constructs. Since the recognition of these subtypes, several groups have studied the implications of subtype on local-regional recurrence.
Kyndi et al. 21 collected paraffin-embedded tumor blocks for 1,078 participating patients from the Danish postmastectomy trials who had a minimum of 8 lymph nodes examined. Tissue microarrays were constructed from 1,000 of these patients and then interrogated for expression analysis with standard immunohistochemical methods. With a median follow-up of 17 years, they found that triple-negative status and receptor-negative/Her-2 positive (Her-2 driven) were prognostic for LRR and overall mortality. Of all variables, only nodal status correlated more strongly with all endpoints (LRR, DM, and mortality) compared with Her-2 driven tumors. Of patients randomized to observation after mastectomy (n = 510), triplenegative tumors were associated with inferior overall mortality, DM rate, and LRR probability. Her-2 tumors were associated with mortality and DM but not LRR. In patients treated with PMRT (n = 486), triple-negative status was associated with worse LRR but did not correlate with survival or metastasis rate. In this large cohort of postmastectomy patients, it is telling that triple-negative status and Her-2-enriched status were the strongest associations with LRR, exceeding even nodal status and tumor size. Paradoxically, PMRT only appeared to benefit patients with favorable biologic subtypes (constructed luminal A) with no statistical improvement in mortality for patients with luminal B, triple-negative, and Her-2 subtypes.
Voduc et al. 22 also analyzed biologic subtype as a predictor of local-regional recurrence in more than 4,000 women treated in the British Columbia Cancer Agency (BCCA) system. Approximately 1,500 of these women were postmastectomy patients. Basal and Her-2 positive subtypes predicted for higher rates of local and regional failure in both postlumpectomy and postmastectomy cohorts. Nonluminal A subtypes were found to be independent variables for risk of chest wall and regional nodal failure on Cox multivariate analysis. The 10-year, local, relapse-free survival for luminal A patients was 92 %, whereas the regional relapse-free survival was 96 % and the corresponding rates were 81 and 80 % for basal subtype.
Dominici et al. 23 reported on a cohort of 819 postmastectomy patients at the MD Anderson Cancer Center. While most of these patients received systemic therapy at the discretion of their treating oncologist, none received PMRT. Many patients in this analysis were either T1 (75 %) or N0 (72 %); another 27 % (219/819) had 1-3 positive lymph nodes. The 5-year risk of LRR was only 2.5 % at a median follow-up time of 58 months. However, patients with triple-negative tumors had a 10.9 % incidence of LRR, which was higher than other phenotypes (p \ 0.01). On multivariate analysis, having four or more positive lymph nodes and triple-negative status were significant predictors of LRR.
Wang et al. 24 recently reported a multicenter, randomized trial that evaluated the benefit of PMRT in triplenegative breast cancer patients. A total of 681 women were randomly assigned to receive either observation or 50 Gy in 25 fractions to the chest wall ± regional lymph nodes after a mastectomy and systemic chemotherapy. All Similar to the studies cited, our report also demonstrates higher odds for local-regional recurrence in hormonereceptor negative and triple-negative phenotypes compared with hormone-receptor positive tumors. Our study is unique in that we began with a cohort of patients with low/ intermediate risk Stage I and II tumors who suffered chest wall or nodal failures and matched these to similar controls without recurrence. In contrast to some of our earlier work, we did not find associations with either p53 or Cox-2 expression in this cohort; this may be due to the contrasting clinical context of these studies (low-intermediate risk patients undergoing mastectomy in current study vs. prior studies with early-stage breast cancer patients undergoing breast conservation). In addition, our report has several limitations that need to be considered. Our study cohort is small and the data were abstracted retrospectively from patient events that occurred over a long study interval. However, given that locoregional recurrences are uncommon in this medium-risk population, smaller study cohorts are to be expected. Nonetheless, our work is subject to the usual, well-described limitations of such analyses. By constructing a TMA of study specimens, we were able to remove the effects of differential assay techniques and assess specimens that were not routinely tested for surface receptors in the earlier time periods. Taken together, our data and that of others suggest that triple-negative phenotype can be considered a contributing risk factor in the decision-making for postmastectomy radiation.
